Abstract
Acute kidney injury (AKI) in cancer patients is a dreadful complication that causes substantial morbidity and mortality. Moreover, AKI may preclude optimal cancer treatment by requiring a decrease in chemotherapy dosage or by contraindicating potentially curative treatment. The pathways leading to AKI in cancer patients are common to the development of ARF in other conditions. However, AKI may also develop because of etiologies arising from cancer treatment, such as nephrotoxic chemotherapy agents, or the disease itself, including post-renal obstruction, compression or infiltration, and metabolic or immunological mechanisms.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
